- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Derms protest planned FDA ban
Schaumburg, Ill. - The American Academy of Dermatology (AAD) will object to a proposed federal ban of over-the-counter sales of hydroquinone.
Schaumburg, Ill. - The American Academy of Dermatology (AAD) will object to a proposed federal ban of over-the-counter sales of hydroquinone.
The Food and Drug Administration (FDA) has declared that products containing the bleaching agent pose risks of cancer and skin discoloration, and has proposed a ban on nonprescription sales.
If the agent is banned, all existing cosmetic products containing hydroquinone would need to submit a new drug application for the FDA's review, according to news reports.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
